{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:48:55Z","timestamp":1782434935033,"version":"3.54.5"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.drudis.2020.11.004","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:22:59Z","timestamp":1605241379000},"page":"551-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Oral meropenem for superbugs: challenges and opportunities"],"prefix":"10.1016","volume":"26","author":[{"given":"Aun","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih Chen","family":"Ngieng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fekade Bruck","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Cabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Kumeria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2020.11.004_bib0005","series-title":"Functional and Preservative Properties of Phytochemicals","first-page":"119","article-title":"Antimicrobial properties of selected plants used in traditional Chinese medicine","author":"Lal","year":"2020"},{"key":"10.1016\/j.drudis.2020.11.004_bib0010","series-title":"Microbiomics","first-page":"279","article-title":"Legacy and innovative treatment: projected modalities for antimicrobial intervention","author":"Al Sorkhy","year":"2020"},{"key":"10.1016\/j.drudis.2020.11.004_bib0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13756-018-0336-y","article-title":"Estimating the burden of antimicrobial resistance: a systematic literature review","volume":"7","author":"Naylor","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.drudis.2020.11.004_bib0020","first-page":"10","article-title":"How to stop the spreading of super bacteria?","volume":"7","author":"Jacome","year":"2019","journal-title":"Brasil Para Todos-Revista Internacional"},{"key":"10.1016\/j.drudis.2020.11.004_bib0025","series-title":"The Copenhagen recommendations. Report from the Inventational EU Conference on the Microbial Threat","author":"Rosdahl","year":"2002"},{"key":"10.1016\/j.drudis.2020.11.004_bib0030","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1073\/pnas.082188899","article-title":"Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria","volume":"99","author":"Smith","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2020.11.004_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/jac\/dkg483","article-title":"Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data","volume":"53","author":"Phillips","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drudis.2020.11.004_bib0040","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.eimc.2014.10.004","article-title":"Resistencia bacteriana a los antibi\u00f3ticos: una crisis global","volume":"33","author":"Al\u00f3s","year":"2015","journal-title":"Enfermedades Infecciosas y Microbiol. Cl\u00edn."},{"key":"10.1016\/j.drudis.2020.11.004_bib0045","article-title":"A review on antibiotic resistance: alarm bells are ringing","volume":"9","author":"Zaman","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.drudis.2020.11.004_bib0050","first-page":"1","article-title":"I.v. or oral antibiotic therapy: Sophie\u2019s choice?","volume":"4","author":"Gajdacs","year":"2019","journal-title":"Gen. Internal Med. Clin. Innovations"},{"key":"10.1016\/j.drudis.2020.11.004_bib0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative Review of the Carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2020.11.004_bib0060","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1134\/S1068162019040125","article-title":"Synthesis and in vitro antibacterial activity of new C-3-modified carbapenems","volume":"45","author":"Valiullina","year":"2019","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.drudis.2020.11.004_bib0065","first-page":"1","article-title":"Pharmacodynamics of antimicrobial agents: time-dependent vs concentration-dependent killing","author":"Quintiliani","year":"2001","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.drudis.2020.11.004_bib0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/cc6994","article-title":"Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use","volume":"12","author":"Slama","year":"2008","journal-title":"Crit. Care"},{"key":"10.1016\/j.drudis.2020.11.004_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4236\/pp.2018.99029","article-title":"Antibiotic use in a cohort of extremely low birth weight neonates: focus on off\u2013label uses and prescription behaviour","volume":"9","author":"Cuzzolin","year":"2018","journal-title":"Pharmacol. Pharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0080","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2147\/IDR.S150447","article-title":"Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae","volume":"11","author":"Petty","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.drudis.2020.11.004_bib0085","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.drudis.2019.01.004","article-title":"Solid nanoparticles for oral antimicrobial drug delivery: a review","volume":"24","author":"Raza","year":"2019","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.drudis.2020.11.004_bib0090","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"1808","author":"Brunton","year":"2011"},{"key":"10.1016\/j.drudis.2020.11.004_bib0095","series-title":"Nanostructures for Oral Medicine","first-page":"173","article-title":"Challenges in oral drug delivery: a nano-based strategy to overcome","author":"Viswanathan","year":"2017"},{"key":"10.1016\/j.drudis.2020.11.004_bib0100","series-title":"Drug Delivery","author":"Popescu","year":"2011"},{"key":"10.1016\/j.drudis.2020.11.004_bib0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2020.11.004_bib0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2020.11.004_bib0115","first-page":"31087","article-title":"Oral absorption, intestinal metabolism and human oral bioavailability","volume":"10","author":"El\u2013Kattan","year":"2012","journal-title":"Top. Drug Metab."},{"key":"10.1016\/j.drudis.2020.11.004_bib0120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1469-0691.1996.tb00194.x","article-title":"Switch therapy: the theory and practice of early change from parenteral to non-parenteral antibiotic administration","volume":"2","author":"Hamilton-Miller","year":"1996","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drudis.2020.11.004_bib0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/43.4.601","article-title":"Early switch from i.v. to oral antibiotics: guidelines and implementation in a large teaching hospital","volume":"43","author":"Sevin\u00e7","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drudis.2020.11.004_bib0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00001432-200012000-00004","article-title":"Sequential antibiotic therapy","volume":"13","author":"Barlow","year":"2000","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.drudis.2020.11.004_bib0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199528040-00002","article-title":"Meropenem clinical pharmacokinetics","volume":"28","author":"Mouton","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drudis.2020.11.004_bib0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4140\/TCP.n.2019.187","article-title":"A brief review of a new antibiotic: meropenem-vaborbactam","volume":"34","author":"Gibson","year":"2019","journal-title":"Senior Care Pharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.drudis.2020.11.004_bib0150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5530\/jyp.2017.9.84","article-title":"Solubility and dissolution enhancement of meropenem by nano suspension approach","volume":"9","author":"Chirumamilla","year":"2017","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0155","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225163","article-title":"The successful treatment of a multidrug-resistant Achromobacter xylosoxidans corneal ulcer with topical meropenem","volume":"2018","author":"Tavassoli","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.drudis.2020.11.004_bib0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14787210.2019.1610392","article-title":"Developments on antibiotics for multidrug resistant bacterial Gram-negative infections","volume":"17","author":"Voulgaris","year":"2019","journal-title":"Exp. Rev. Anti-Infective Ther."},{"key":"10.1016\/j.drudis.2020.11.004_bib0165","first-page":"1143","article-title":"Mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates","volume":"15","author":"Ye","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2020.11.004_bib0170","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/590064","article-title":"Pharmacokinetic and pharmacodynamic properties of meropenem","volume":"47","author":"Nicolau","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drudis.2020.11.004_bib0175","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jac\/dkz514","article-title":"Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm","volume":"75","author":"Alam","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drudis.2020.11.004_bib0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpba.2019.01.039","article-title":"A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM","volume":"169","author":"Zou","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.drudis.2020.11.004_bib0185","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1007\/s00216-020-02545-4","article-title":"Towards point of care systems for the therapeutic drug monitoring of imatinib","volume":"412","author":"Pearce","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.drudis.2020.11.004_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2018-227124","article-title":"Meropenem-induced liver injury and beta-lactam cross-reactivity","volume":"11","author":"Tattersall","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.drudis.2020.11.004_bib0195","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2009.11.012","article-title":"Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses","volume":"35","author":"Martin-Canal","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.drudis.2020.11.004_bib0200","doi-asserted-by":"crossref","first-page":"O831","DOI":"10.1111\/1469-0691.12677","article-title":"In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae","volume":"20","author":"Harada","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drudis.2020.11.004_bib0205","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jmii.2019.04.008","article-title":"Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia","volume":"52","author":"Liu","year":"2019","journal-title":"J. Microbiol., Immunol. Infect."},{"key":"10.1016\/j.drudis.2020.11.004_bib0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/antibiotics8040255","article-title":"Ceftazidime\u2013avibactam versus meropenem for the treatment of complicated intra-abdominal infections","volume":"8","author":"Tan","year":"2019","journal-title":"Antibiotics"},{"key":"10.1016\/j.drudis.2020.11.004_bib0215","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open\u2013label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit. Care"},{"key":"10.1016\/j.drudis.2020.11.004_bib0220","doi-asserted-by":"crossref","first-page":"e230144","DOI":"10.1136\/bcr-2019-230144","article-title":"Meropenem-induced Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity","volume":"12","author":"Sameed","year":"2019","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.drudis.2020.11.004_bib0225","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00002018-200730080-00002","article-title":"Safety profile of meropenem","volume":"30","author":"Linden","year":"2007","journal-title":"Drug Safety"},{"key":"10.1016\/j.drudis.2020.11.004_bib0230","first-page":"110","article-title":"Meropenem\u2013vaborbactam (Vabomere\u2122): another option for carbapenem-resistant Enterobacteriaceae","volume":"44","author":"Lee","year":"2019","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.drudis.2020.11.004_bib0235","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4236\/pp.2012.32027","article-title":"Possible factors involved in oral inactivity of meropenem, a carbapenem antibiotic","volume":"3","author":"Saito","year":"2012","journal-title":"Pharmacol. Pharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0240","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.drudis.2020.11.004_bib0245","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jpba.2004.11.023","article-title":"Chromatographic determination of polymerized impurities in meropenem","volume":"37","author":"Cai","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.drudis.2020.11.004_bib0250","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1136\/ejhpharm-2018-001699","article-title":"Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting","volume":"27","author":"Jamieson","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0255","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0018578718779009","article-title":"Stability of meropenem after reconstitution for administration by prolonged infusion","volume":"54","author":"Fawaz","year":"2019","journal-title":"Hosp. Pharmacy"},{"key":"10.1016\/j.drudis.2020.11.004_bib0260","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1016\/j.bmc.2013.05.024","article-title":"Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis","volume":"21","author":"Teitelbaum","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2020.11.004_bib0265","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3109\/00498259309059441","article-title":"The disposition and metabolic fate of 14C-meropenem in man","volume":"23","author":"Harrison","year":"1993","journal-title":"Xenobiotica"},{"key":"10.1016\/j.drudis.2020.11.004_bib0270","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2020.11.004_bib0275","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/clinids\/24.Supplement_2.S249","article-title":"Pharmacokinetics of meropenem in animals, healthy volunteers, and patients","volume":"24","author":"Moon","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drudis.2020.11.004_bib0280","doi-asserted-by":"crossref","first-page":"19146","DOI":"10.1021\/ja307803m","article-title":"Recognition of imipenem and meropenem by the RND-transporter MexB studied by computer simulations","volume":"134","author":"Collu","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2020.11.004_bib0285","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.mib.2009.07.003","article-title":"Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update","volume":"12","author":"Blair","year":"2009","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.drudis.2020.11.004_bib0290","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.43.2.424","article-title":"Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems","volume":"43","author":"K\u00f6hler","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2020.11.004_bib0295","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/13543784.11.4.529","article-title":"Recent developments in carbapenems","volume":"11","author":"Bonfiglio","year":"2002","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.drudis.2020.11.004_bib0300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejpb.2015.10.013","article-title":"\u03b2-Cyclodextrin complexation as an effective drug delivery system for meropenem","volume":"99","author":"Paczkowska","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0305","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ja.2010.164","article-title":"Novel prodrugs of meropenem with two lipophilic promoieties: synthesis and pharmacokinetics","volume":"64","author":"Tanaka","year":"2011","journal-title":"J. Antibiot."},{"key":"10.1016\/j.drudis.2020.11.004_bib0310","doi-asserted-by":"crossref","first-page":"e00603","DOI":"10.1128\/AAC.00603-19","article-title":"Pharmacodynamics of tebipenem: new options for oral treatment of multidrug-resistant Gram-negative infections","volume":"63","author":"McEntee","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2020.11.004_bib0315","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/03639045.2015.1044902","article-title":"Solid-state stability studies of crystal form of tebipenem","volume":"42","author":"Talaczy\u0144ska","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0320","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jps.21114","article-title":"Effect of P\u2010glycoprotein expression levels on the concentration\u2010dependent permeability of drugs to the cell membrane","volume":"97","author":"Shirasaka","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2020.11.004_bib0325","first-page":"1590","article-title":"The drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Cremophor","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drudis.2020.11.004_bib0330","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jps.20017","article-title":"Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes","volume":"93","author":"Shono","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2020.11.004_bib0335","first-page":"260","article-title":"Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2)","volume":"76","author":"Hanke","year":"2010","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0340","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0928-0987(02)00055-6","article-title":"Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers","volume":"16","author":"Rege","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2020.11.004_bib0345","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ejpb.2009.03.008","article-title":"In vivo evaluation of thiolated poly (acrylic acid) as a drug absorption modulator for MRP2 efflux pump substrates","volume":"72","author":"Greindl","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2020.11.004_bib0350","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2005.11.011","article-title":"Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine","volume":"111","author":"Werle","year":"2006","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.drudis.2020.11.004_bib0355","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1016\/j.biomaterials.2011.03.005","article-title":"The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles","volume":"32","author":"Mo","year":"2011","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.drudis.2020.11.004_bib0360","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1023\/A:1026179132599","article-title":"Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85","volume":"20","author":"Batrakova","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2020.11.004_bib0365","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1208\/s12249-010-9489-6","article-title":"Formulation and in vitro characterization of Eudragit\u00ae L100 and Eudragit\u00ae L100-PLGA nanoparticles containing diclofenac sodium","volume":"11","author":"Cetin","year":"2010","journal-title":"Aaps Pharmscitech."},{"key":"10.1016\/j.drudis.2020.11.004_bib0370","first-page":"219","article-title":"Reduced ABCB1 expression and activity in the presence of acrylic copolymers","volume":"4","author":"Mohammadzadeh","year":"2014","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.drudis.2020.11.004_bib0375","first-page":"43","article-title":"Design of vancomycin RS\u2013100 nanoparticles in order to increase the intestinal permeability","volume":"2","author":"Loveymi","year":"2012","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.drudis.2020.11.004_bib0380","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbalip.2012.06.001","article-title":"Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements","volume":"1821","author":"Simon","year":"2012","journal-title":"Biochim. Biophys. Acta \u2013Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.drudis.2020.11.004_bib0385","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0006-2952(00)00451-2","article-title":"Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats","volume":"60","author":"Lo","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2020.11.004_bib0390","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-5793(03)00059-0","article-title":"Involvement of cholesterol in the inhibitory effect of dimethyl-\u03b2-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells","volume":"536","author":"Yunomae","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drudis.2020.11.004_bib0395","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijbiomac.2013.04.074","article-title":"Effects of \u03b2-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate","volume":"59","author":"Zhang","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.drudis.2020.11.004_bib0400","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2013.05.012","article-title":"Investigation of transport of genistein, daidzein and their inclusion complexes prepared with different cyclodextrins on Caco\u20132 cell line","volume":"84","author":"Daruh\u00e1zi","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.drudis.2020.11.004_bib0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0973-8398.154688","article-title":"Influence of excipients on drug absorption via modulation of intestinal transporters activity","volume":"9","author":"Thakkar","year":"2015","journal-title":"Asian J. Pharmaceutics"},{"key":"10.1016\/j.drudis.2020.11.004_bib0410","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/mp900191s","article-title":"Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access","volume":"7","author":"Collnot","year":"2010","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.drudis.2020.11.004_bib0415","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/092986710790416290","article-title":"Development of nanoparticles for antimicrobial drug delivery","volume":"17","author":"Zhang","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2020.11.004_bib0420","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.colsurfb.2015.04.021","article-title":"Advanced biopolymer-coated drug-releasing titania nanotubes (TNTs) implants with simultaneously enhanced osteoblast adhesion and antibacterial properties","volume":"130","author":"Kumeria","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.drudis.2020.11.004_bib0425","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1021\/acs.biomac.6b00786","article-title":"Naturally derived Iron oxide nanowires from Bacteria for magnetically triggered drug release and Cancer hyperthermia in 2D and 3D culture environments: Bacteria biofilm to potent cancer therapeutic","volume":"17","author":"Kumeria","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.drudis.2020.11.004_bib0430","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jconrel.2020.05.002","article-title":"Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides","volume":"324","author":"Ndayishimiye","year":"2020","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.drudis.2020.11.004_bib0435","first-page":"1","article-title":"Mesoporous silica nanoparticles: synthesis methods and their therapeutic use-recent advances","author":"Mohsen Ghaferi","year":"2020","journal-title":"J. Drug Targeting"},{"key":"10.1016\/j.drudis.2020.11.004_bib0440","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12011-016-0909-7","article-title":"Rutin\u2013nickel complex: synthesis, characterization, antioxidant, DNA binding, and DNA cleavage activities","volume":"178","author":"Raza","year":"2017","journal-title":"Biol. Trace Eleme. Res."},{"key":"10.1016\/j.drudis.2020.11.004_bib0445","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ph13030044","article-title":"Preparation, characterization, and evaluation of cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved in vitro and in vivo anticancer activities","volume":"13","author":"Ghaferi","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2020.11.004_bib0450","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s10895-016-1896-y","article-title":"Quercetin-iron complex: synthesis, characterization, antioxidant, DNA binding, DNA cleavage, and antibacterial activity studies","volume":"26","author":"Raza","year":"2016","journal-title":"J. Fluoresc."},{"key":"10.1016\/j.drudis.2020.11.004_bib0455","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/17425247.2017.1317245","article-title":"Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives","volume":"14","author":"Kumeria","year":"2017","journal-title":"Expert Opin. Drug Delivery"},{"key":"10.1016\/j.drudis.2020.11.004_bib0460","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jconrel.2020.07.021","article-title":"Silica nanoparticles: a promising platform for enhanced oral delivery of macromolecules","volume":"326","author":"Abeer","year":"2020","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.drudis.2020.11.004_bib0465","series-title":"Characterization and Biology of Nanomaterials for Drug Delivery","first-page":"587","article-title":"Administration routes for nano drugs and characterization of nano drug loading","author":"Nikoli\u0107","year":"2019"},{"key":"10.1016\/j.drudis.2020.11.004_bib0470","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/pharmaceutics11080418","article-title":"Rationally designed dendritic silica nanoparticles for oral delivery of exenatide","volume":"11","author":"Abeer","year":"2019","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.drudis.2020.11.004_bib0475","first-page":"649","article-title":"Pharmaceutical nanotechnology in Egypt: diverse applications and promising outcomes","volume":"14","author":"Elzoghby","year":"2019","journal-title":"Fut. Med."},{"key":"10.1016\/j.drudis.2020.11.004_bib0480","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.drudis.2014.04.011","article-title":"Is nanotechnology a boon for oral drug delivery?","volume":"19","author":"Agrawal","year":"2014","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.drudis.2020.11.004_bib0485","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3389\/fmicb.2018.01441","article-title":"Nano\u2013strategies to fight multidrug resistant bacteria\u2014\u201cA Battle of the Titans\u201d","volume":"9","author":"Baptista","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.drudis.2020.11.004_bib0490","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.carbpol.2017.07.030","article-title":"Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model","volume":"174","author":"Abdelkader","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.drudis.2020.11.004_bib0495","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.biopha.2013.02.004","article-title":"High glycolic poly (DL lactic co glycolic acid) nanoparticles for controlled release of meropenem","volume":"67","author":"Nandakumar","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2020.11.004_bib0500","series-title":"MERREM\u00ae IV (Meropenem for Injection)","author":"FDA","year":"2016"},{"key":"10.1016\/j.drudis.2020.11.004_bib0505","series-title":"Applications of Nanocomposite Materials in Drug Delivery","first-page":"217","article-title":"Polymer nanoparticle carriers in drug delivery systems: Research trend","author":"Lim","year":"2018"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620304694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620304694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:48:47Z","timestamp":1761223727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620304694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1359644620304694"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.11.004","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral meropenem for superbugs: challenges and opportunities","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}